MaxCyte, Inc. is listed today as MaxCyte, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2014 | $2 M | No. 2 | Under $2 million | equity | SEC | |
| Aug 2009 | $2 M | No. 1 | Under $2 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company MaxCyte, Inc., its revenue in fiscal 2025 came from these product and service lines: Licenses $12.37 million (37%), Assay and other service revenue $1.97 million (6%).
Annual report (SEC XBRL) · Dec 2025
MaxCyte, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2014).
SEC Form D · Dec 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2014
Products and services#
No products or services of MaxCyte, Inc. are on record.
Investors#
No investor of MaxCyte, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 21 investors.
Largest shareholders today
Institutions holding MaxCyte, Inc. shares, as of Sep 30, 2026.
- Capricorn Fund Managers Ltd$9 M7.94%
- Vitruvian Partners LLP$6 M4.88%
- Liontrust Investment Partners LLP$5 M4.69%
- Vanguard Capital Management LLC$4 M3.88%
- Morgan Stanley$4 M3.86%
- BlackRock, Inc.$3 M2.93%
- BNP PARIBAS ASSET MANAGEMENT Holding S.A.$3 M2.69%
- Cadian Capital Management, LP$3 M2.54%
- Two Sigma Investments, LP$3 M2.33%
- Mudita Advisors LLP$3 M2.19%
- Renaissance Technologies LLC$2 M1.97%
- Peapod Lane Capital LLC$2 M1.92%
- RBF Capital, LLC$2 M1.57%
- Brooklands Fund Management Ltd$2 M1.52%
- Marshall Wace, LLP$2 M1.51%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Douglas A. Doerfler | Executive officer | Dec 2014 |
| Karen Stark Donato | Executive officer | Dec 2014 |
| Madhusudan E. Peshwa | Executive officer | Dec 2014 |
| Ronald E. Holtz | Executive officer | Dec 2014 |
| Karen Starke Donato | Executive officer | Oct 2009 |
| Madhusadan E. Peshwa | Executive officer | Oct 2009 |
| Karen Donato | Executive officer | Aug 2009 |
| Madhusadan Peshwa | Executive officer | Aug 2009 |
| Arthur Stark Mandell | Director | Dec 2014 |
| Dennis Stark Dougherty | Director | Dec 2014 |
| Douglas A. Doerfler | Director | Dec 2014 |
| J. Stark Thompson | Director | Dec 2014 |
| Sinclair Stark Dunlop | Director | Dec 2014 |
| Stan Stark Erck | Director | Dec 2014 |
| Will Stark Brooke | Director | Dec 2014 |
| Arthur Starke Mandell | Director | Oct 2009 |
| Chris Starke Hegele | Director | Oct 2009 |
| David Starke Pierson | Director | Oct 2009 |
| J. Starke Thompson | Director | Oct 2009 |
| Sinclair Starke Dunlop | Director | Oct 2009 |
| Stan Starke Erck | Director | Oct 2009 |
| Will Starke Brooke | Director | Oct 2009 |
| Arthur Mandell | Director | Aug 2009 |
| Chris Hegele | Director | Aug 2009 |
| David Pierson | Director | Aug 2009 |
| Sinclair Dunlop | Director | Aug 2009 |
| Stan Erck | Director | Aug 2009 |
| Will Brooke | Director | Aug 2009 |
About
Biotech company in Rockville, United States.
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.